ArcticZymes Technologies ASA (AZT) Fair Value & Analysis
Healthcare · NO · Market cap 963M NOK
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price +2.1% over the past month.
A solid business, but screening 78% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 4.72). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range kr 12.74 – kr 107.40 · fair‑value band kr 3.19 – kr 4.72 · the kr 19.50 price screens above the kr 4.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
ArcticZymes Technologies ASA (AZT) currently trades at kr 19.50, while our model-based Fair Value estimate is kr 4.26, implying the stock looks roughly 78.2% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, ArcticZymes Technologies ASA generated revenue of 128M NOK at a net margin of 10.5%. Revenue grew 40.9% year over year. It earns a return on equity of 4.1%. The balance sheet holds a net cash position of 181M NOK. Fundamentals as of Jul 20, 2026
Our scenario range runs from kr 3.19 (bear case) to kr 4.72 (bull case); at kr 19.50, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -78%, AZT screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (kr 8.15) versus Earnings-Based (kr 1.62). Highest evidence: Growth DCF (72).
Notify me when AZT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing.
Full company description
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ArcticZymes Technologies ASA reported revenue of kr 113M in FY2025 versus kr 128M in FY2021, a compound −3.1%/yr. Reported net income was kr 9.9M in FY2025, compounding −32.1%/yr from FY2021.
AZT screens 78% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare ArcticZymes Technologies ASA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ArcticZymes Technologies ASA (AZT) overvalued or undervalued?
What is the fair value of AZT?
What is the quality score of AZT?
What is the revenue of ArcticZymes Technologies ASA (AZT)?
What is the net profit margin of AZT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ArcticZymes Technologies ASA and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.